ClinicalTrials.gg
Sign In
CompletedNCT07870200Updated Oct 15, 2026

Flexible Ureteroscopy Versus Mini- Percutaneous Nephrolithotomy in Management of Pediatric Renal Stones Less Than 2 cm

An interventional study of Group A :Flexible ureteroscope group and Group B : Mini perc group in Renal Stone and Pediatric, sponsored by Elsayed Abdelhalim Elsayed. Completed at 1 site in Egypt. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Elsayed Abdelhalim Elsayed · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jun 2023, registered Oct 2026).
Updated Oct 15, 2026Eligibility revisedNewly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Study summary

This single-center, prospective, two-arm randomized controlled trial included 58 patients younger than 18 years who were allocated 1:1 to Mini-PCNL or FURS between June 2023 and December 2024. The primary outcome was the six-week stone-free rate (SFR), defined as complete absence of residual fragments on postoperative imaging. Secondary outcomes included operative time, fluoroscopy time, hospital stay, auxiliary procedures, hemoglobin measurements, and postoperative complications.

02

Conditions studied

  • Renal Stone
  • Pediatric

Browse trials for

03

In context

Nephrolithiasis

467 studies on the registry are indexed under Nephrolithiasis; 108 are open to participants now.

This study's enrollment of 60 is below the median of 90 across 365 interventional studies indexed under Nephrolithiasis.

Browse Nephrolithiasis studies →

Lead sponsor

Elsayed Abdelhalim Elsayed is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pediatric patients \<18 years old (according to American Academy of Pediatrics (AAP)
  • Solitary renal with a size ranging from 1 to 2 cm .

Exclusion criteria

Exclusion Criteria:

  • involved multiple or very small/large stones,
  • adult over 18 years old,
  • BMI > 40 kg/m²,
  • bleeding disorders,
  • congenital renal anomalies,
  • distal obstruction, or
  • musculoskeletal deformities.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group A :Flexible ureteroscope group

    Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy

    Procedure: Group A :Flexible ureteroscope group

  • Active comparator
    Group B: Mini perc group

    Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.

    Procedure: Group B : Mini perc group

Interventions

  • ProcedureGroup A :Flexible ureteroscope group

    Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy

  • ProcedureGroup B : Mini perc group

    Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.

06

What researchers measure

Primary outcomes

  1. stone free rate

    Time frame: Six weeks from primary procedure

Secondary outcomes

  1. Post operative complication

    Time frame: Up to 48 houra

07

Study locations

1 site
  • Elsayed Abdelhalim
    Kafr ash Shaykh, Select State 44749, Egypt
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Dec 2024, 18 months.

Of 177 non-industry interventional studies with no phase under Nephrolithiasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 18 months is below that.

Counting every sponsor, half of 185 studies reached it within 24 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartActual
Jun 1, 2023
Primary completionActual
Dec 1, 2024
CompletionActual
Dec 1, 2024
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Also revised
eligibility
Registered
First appeared on the registry
Oct 13, 2026
Show all 2 updates
  1. Oct 15, 2026
    Eligibility Criteria revised
    + 1 other change: identifiers
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07870200
Lead sponsor
Elsayed Abdelhalim Elsayed
Responsible party
Elsayed Abdelhalim Elsayed (Principal Investigator, Kafrelsheikh University) — Sponsor-investigator
First posted
Oct 13, 2026
Start date
Jun 1, 2023
Primary completion
Dec 1, 2024
Completion
Dec 1, 2024
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nephrolithiasis →

Other studies from this sponsor

Elsayed Abdelhalim Elsayed

Start the discussion